Time for (More Research on) Testosterone
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
In this issue of JCEM, Amory et al. (1) present the most impressive results yet published from a placebo-controlled clinical trial evaluating the effect of testosterone therapy on hip and spine bone density in older men with low testosterone levels. To determine whether bone benefit could be achieved with little or no effect on prostate size, symptoms, or prostate-specific antigen (PSA) levels, the investigators compared placebo with 200 mg of im testosterone enanthate every 2 wk, given alone or with finasteride. After 36 months, the addition of finasteride did not significantly modify the marked increase in bone mineral density (BMD) observed with testosterone. There was a 9–10% increase in BMD at the lumbar spine and a 2–3% increase in BMD at the hip, as determined by dual-energy x-ray absorptiometry, with each increase significantly better than the observed changes in the placebo group and not significantly different from each other. This trial offers proof of the principle that testosterone treatment preserves bone in older men with low testosterone levels, but are the results clinically relevant? The study was generally well designed, and the key elements of good clinical trials are clearly described: the sample, the computer-generated randomization process, the blind (which included a dual-energy x-ray absorptiometry reader unaware of treatment assignment), the main entry criteria (total testosterone levels < 350 ng/dl on two occasions and a PSA < 4 ng/ml), the primary outcome (BMD at the spine and hip), the compliance rate (95% for completers), the completion rate (71%), and the sophisticated analysis plan. Unfortunately, the testosterone regimen used in this trial was associated with a high frequency of erythrocytosis. In the present study, 30% of the men assigned to the testosterone group required a reduction of the dose of testosterone to manage a hematocrit increase of 52% or greater. These men then received a testosterone dose of about 150 mg every 2 wk, suggesting that the 200-mg dose may not be necessary for bone benefit. The dose is important because the BMD changes observed in the present study are much more impressive than those reported in other placebo-controlled trials of testosterone and bone density, most likely because of the lower dose of testosterone delivered. For example, there were no significant changes in BMD in another controlled trial at half the dose (100 mg testosterone enanthate every 2 wk) (2). Kenny et al. (3) reported less bone loss at the femoral neck but not at the spine in 44 men treated with placebo or 5 mg of testosterone administered daily by patch for 12 months. Snyder et al. (4) reported no significant differences in BMD at any site after 36 months of 6 mg of daily testosterone by scrotal patch compared with placebo, although a subset analysis showed significantly better bone density in the men who had the lowest testosterone levels at baseline. The large increase in spine BMD observed here is similar to that achieved in postmenopausal women after 3 yr of treatment with a bisphosphonate (5). Increases in BMD, however, only incompletely predict reductions in fracture risk (5, 6). As Morley (7) has pointed out, fear of prostate disease is the 800-lb gorilla confounding decisions about the use of testosterone replacement therapy. In animal models, testosterone and dihydrotestosterone (DHT) therapy can cause prostate hypertrophy and cancer, but the relevance of these studies for humans is uncertain (8). Evidence is limited that higher doses of testosterone are more likely than lower doses to have adverse effects on the prostate, at least in younger men (9). Testosterone undergoes conversion to DHT by steroid 5α-reductase within the prostate, an effect blocked by finasteride, a 5α-reductase inhibitor. In a recent clinical trial, finasteride reduced prostate cancer risk by 25% (10). A novel addition to the present clinical trial was the comparison of testosterone alone with testosterone plus finasteride. The former but not the combination increased PSA significantly compared with placebo, and prostate volume increased significantly less in the testosterone plus finasteride group compared with the testosterone-only or placebo groups. As the authors note, men treated with the combination of testosterone and finasteride reduced their DHT by 50%, but not completely, and some DHT may be required for bone benefit. Further, testosterone plus finasteride increased serum estradiol and testosterone levels more than testosterone alone, reflecting the increase in LH secretion due to inhibition of 5α-reductase in the pituitary. In observational studies, endogenous estradiol appears to be as important, or more important, than testosterone in bone maintenance (11). Just how testosterone works to preserve bone is not clear, but the results of this study raise the possibility that a bone-sparing, prostate-sparing testosterone regimen may be feasible. But just as improved bone density
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967 · cited 1×
“Evidence is limited that higher doses of testosterone are more likely than lower doses to have adverse effects on the prostate, at least in younger men (9).”
BackgroundSelf-citationAmory, J. K., Watts, N. B., Easley, K. A., Sutton, P. R., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031110 · Cited by 475 · cited 1×
“(1) present the most impressive results yet published from a placebo-controlled clinical trial evaluating the effect of testosterone therapy on hip and spine bone density in older men with low testosterone levels.”
BackgroundEffect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.6.1966 · Cited by 460
Kenny, A. M., Prestwood, K. M., Gruman, C. A., Marcello, K. M., & Raisz, L. G. (2001) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/56.5.m266 · Cited by 456
Cited by
Khaw, K.-T., Dowsett, M., Folkerd, E., Bingham, S., Wareham, N., Luben, R., Welch, A., & Day, N. (2007) · Circulation · doi:10.1161/circulationaha.107.719005 · Cited by 743
Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes
Dhindsa, S., Prabhakar, S., Sethi, M., Bandyopadhyay, A., Chaudhuri, A., & Dandona, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0804 · Cited by 631
“This question needs to be addressed in prospective randomized studies (44).”
BackgroundBhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Mac, R. P., Lee, M., Yarasheski, K. E., Sinha-Hikim, I., Dzekov, C., Dzekov, J., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1184 · Cited by 544
Self-citationSvartberg, J., Agledahl, I., Figenschau, Y., Sildnes, T., Waterloo, K., & Jorde, R. (2008) · International Journal of Impotence Research · doi:10.1038/ijir.2008.19 · Cited by 160
Metadata
- Authors
- Barrett-Connor, E., & Bhasin, S.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-02
- Volume
- 89
- Issue
- 2
- Pages
- 501-502
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2089518644
- Cited by
- 20
- References
- 4
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.